Effects of imatinib mesylate (gleevec) on human islet NF-kappaB activation and chemokine production in vitro

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Mokhtari, Dariush ^a   Li, Tingting ^a   Lu, Tao ^b   Welsh, Nils ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; I KAPPA B ALPHA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; STAT1 PROTEIN; TRANSCRIPTION FACTOR RELA; HEAT SHOCK PROTEIN 27; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TANK PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DR5 GENE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HSF27 GENE; HUMAN; HUMAN CELL; I CAM GENE; I TRAF GENE; IL 4R GENE; IL8 GENE; IMMUNOBLOTTING; IN VITRO STUDY; LONG TERM EXPOSURE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PANCREAS ISLET CELL; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TCF5 GENE; DRUG EFFECT; GENETICS; METABOLISM; METHYLATION; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CHEMOKINES; FLOW CYTOMETRY; HSP27 HEAT-SHOCK PROTEINS; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-8; METHYLATION; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR RELA;

EID: 80052846276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024831     Document Type: Article

References (50)

1. Eizirik D, Mandrup-Poulsen T, (2001) A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44: 2115-33.
2. Cnop M, Welsh N, Jonas J, Jorns A, Lenzen S, et al. (2005) Mechanisms of Pancreatic {beta}-Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities. Diabetes 54S2: S97-S107.
3. Rabson AB, Weissmann D, (2005) From microarray to bedside: targeting NF-kappaB for therapy of lymphomas. Clin Cancer Res 11: 2-6.
4. Xiao C, Ghosh S, (2005) NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol 560: 41-45.
5. Karin M, Cao Y, Greten FR, Li ZW, (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310.
6. Ghobrial IM, Witzig TE, Adjeji AA, (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194.
7. Maekawa T, Ashihara E, Kimura S, (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 12: 327-340.
8. Veneri D, Franchini M, Bonora E, (2005) Imatinib and regression of type 2 diabetes. New Engl J Med 352: 1049-1050.
9. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G, (2004) Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment. J Clin Onocol 22: 4653-4655.
10. Couzin J, (2005) Researchers Puzzle Over Possible Effect of Gleevec. Science 307: 1711.
11. Chodorowski Z, Sein Anand J, Hellmann A, Prejzner W, (2007) No influence of imatinib on type 2 diabetes. Przegl Lek 64: 370-371.
12. Dingli D, Wolf RC, Vella A, (2007) Imatinib and type 2 diabetes. Endocr Pract 13 (2): 126-130.
13. Costa DB, Huberman MS, (2006) Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care 29: 1711.
14. Tsapas A, Vlachaki E, Sarigianni M, Klonizakis F, Paletas K, (2008) Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). Leuk Res 32: 674-675.
15. Breccia M, Muscaritoli M, Alimena G, (2005) Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib. Haematologica Nov: 90 (Suppl): ECR21.
16. Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, et al. (2008) Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 32 (10): 1626-1628.
17. Templeton A, Brändle M, Cerny T, Gillessen S, (2008) Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 19: 824-825.
18. Agostino N, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, et al. (2010) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2010 Aug 4. [Epub ahead of print].
19. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, et al. (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95: 3763-3767.
20. Mariani S, Tornaghi L, Sassone M, Basciani S, Buzzetti R, et al. (2010) Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leuk Res 34 (1): e5-7 Epub 2009 Aug 29.
21. Hägerkvist R, Jansson L, Welsh N, (2008) Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 114: 65-71.
22. Han MS, Chung KW, Cheon HG, Rhee SD, Yoon C-H, et al. (2009) Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 58: 329-336.
23. Gur S, Kadowitz PJ, Hellstrom WJ, (2010) A protein tyrosine kinase inhibitor, imatinib mesylate (gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats. J Sex Med 7: 3341-3350.
24. Hägerkvist R, Sandler S, Mokhtari D, Welsh N, (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21: 618-628.
25. Hägerkvist R, Makeeva N, Elliman S, Welsh N, (2006) Imatinib mesylate (Gleevec) protects against STZ-induced diabetes and islet cell in vitro. Cell Biol Int 30: 1013-7.
26. Louvet C, Szot GL, Lang J, Lee MR, Martiner N, et al. (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 105: 18895-18899.
27. Mokhtari D, Welsh N, (2009) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118: 241-247.
28. Little PJ, Cohen N, Morahan G, (2009) Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. ScientificWorldJournal 9: 224-228.
29. Bluestone JA, Herold K, Eisenbarth G, (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464: 1293-300.
30. Mokhtari D, Barbu A, Mehmeti I, Vercamer C, Welsh N, (2009) Overexpression of the Nuclear Factor-{kappa}B subunit c-Rel protects against human islet cell death in vitro. Am J Physiol Endocrinol Metab 297: E1067-E1077.
31. Goto T, Tanioka Y, Sakai T, Matsumoto I, Kakinoki K, et al. (2005) Successful islet transplantation from a single pancreas harvested from a young, low-BMI, non-heart-beating cadaver. Transplant Proc 37: 3430-3432.
32. Saldeen J, Welsh N, (1994) Interleukin-1βeta induced activation of NF-kappaB in insulin producing RINm5F cells is prevented by the protease inhibitor tosyl-lysine chloromethyl ketone. Biochem Biophys Res Commun 203: 149-155.
33. Lu T, Jackson MW, Wang B, Yang M, Chance, et al. (2010) Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 107: 46-51.
34. Larsen L, Størling J, Darville M, Eizirik DL, Bonny C, et al. (2005) Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia 48: 2582-2590.
35. Chen BC, Kang JC, Lu YT, Hsu MJ, Liao CC, et al. (2009) Rac1 regulates peptidoglycan-induced nuclear factor-kappaB activation and cyclooxygenase-2 expression in RAW 264.7 macrophages by activating the phosphatidylinositol 3-kinase/Akt pathway. Mol Immunol 46: 1179-1188.
36. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C, (2009) Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 15: 5974-5984.
37. Reber L, Vermeulen L, Haegeman G, Frossard N, (2009) Ser276 phosphorylation of NF-κB p65 by MSK1 controls SCF expression in inflammation. PLoS One 4: e4393.
38. Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, et al. (2010) Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65. Cell Death Differ 17: 689-698.
39. Saldeen J, Lee JC, Welsh N, (2001) Role of p38 mitogen-activated protein kinase (p38 MAPK) in cytokine-induced rat islet cell apoptosis. Biochem Pharmacol 61: 1561-1569.
40. Saha RN, Jana M, Pahan K, (2007) MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol 179: 7101-7109.
41. Igoillo-Esteve M, Marselli L, Land D, Cunha A, Ladrière L, et al. (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 53: 1395-1405.
42. Eizirik DL, Flodström M, Karlsen AE, Welsh N, (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39: 875-890.
43. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA, (2010) Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 21: 261-267.
44. Ito CY, Kazantsev AG, Baldwin AS, (1994) Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res 22: 3787-3792.
45. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, et al. (2007) IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 27: 7451-7461.
46. Karlsen AE, Heding PE, Frobøse H, Rønn SG, Kruhøffer, et al. (2004) Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways. Diabetologia 47: 1998-2011.
47. Wullaert A, Verstrepen L, Van Huffel S, Adib-Conquy M, Cornelis S, et al. (2007) LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappaB activation. J Biol Chem 282: 81-90.
48. Zhang W, Wang J, Zhang Y, Yuan Y, Guan W, et al. (2010) The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1. Mol Biol Cell 21: 2500-2513.
49. Nelson G, Wilde JC, Spiller DG, Kennedy SM, Ray DW, et al. (2003) NF-kappaB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci 116: 2495-2503.
50. Liberatore RA, Goff SP, Nunes I, (2009) NF-kappaB activity is constitutively elevated in c-Abl null fibroblasts. Proc Natl Acad Sci U S A 106: 17823-17828.